Auris Medical Holding Ltd. is dedicated to pioneering unconventional medical solutions for neurotology and central nervous system disorders. With its focus on intranasal betahistine, and its other programs like the eskatemine-based Keyzilen (AM-101) and brimapitide-based AM-111 for tinnitus and hearing loss respectively, the company is currently in Phase 1 of clinical trials and looks to continue innovating better treatments. Operating in the United States, Switzerland and Ireland, Auris Medical Holding Ltd. currently employs 11 full-time employees.